Alexion Pharma (ALXN): Products Unimpaired - Leerink

November 10, 2016 8:26 AM EST
Get Alerts ALXN Hot Sheet
Price: $135.30 --0%

Rating Summary:
    20 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 10 | Down: 16 | New: 50
Trade ALXN Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) after the company filed a Form 12b-25 Notification of Late Filing for their Q3 2016 10-Q.

The company disclosed that their board’s Audit and Finance Committee is investigating alleged fraudulent sales practices for Soliris based on allegations made by a former employee. ALXN did not file the third quarter 2016 10-Q by yesterday’s deadline, and has offered no assurance that their quarterly accounts will be filed within the SEC’s five day grace period after the non-timely (NT) notice. From our conversation last night with management, it indeed seems likely that the resolution of this investigation, and the clarification of the company’s re-statements, if needed, will take potentially weeks rather than days.

No change to the price target of $211.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $127.16 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment